Lisanti Capital Growth LLC Buys New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lisanti Capital Growth LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 77,875 shares of the medical equipment provider's stock, valued at approximately $6,253,000. Lantheus accounts for 1.5% of Lisanti Capital Growth LLC's portfolio, making the stock its 17th biggest holding. Lisanti Capital Growth LLC owned 0.11% of Lantheus as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Daiwa Securities Group Inc. purchased a new stake in Lantheus during the 1st quarter valued at about $1,269,000. Clearbridge Investments LLC boosted its holdings in Lantheus by 45.4% during the 4th quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider's stock valued at $33,404,000 after acquiring an additional 168,114 shares during the period. Nordea Investment Management AB boosted its holdings in Lantheus by 42.6% during the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider's stock valued at $2,932,000 after acquiring an additional 14,147 shares during the period. Hancock Whitney Corp boosted its holdings in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock valued at $1,254,000 after acquiring an additional 14,639 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Lantheus during the 2nd quarter valued at about $290,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of several research analyst reports. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Finally, Leerink Partners increased their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $119.00.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,193 shares of company stock valued at $3,949,202. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.6 %

Shares of LNTH traded up $1.66 on Friday, reaching $106.47. The stock had a trading volume of 716,911 shares, compared to its average volume of 801,260. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The firm has a market capitalization of $7.39 billion, a price-to-earnings ratio of 16.25 and a beta of 0.51. The company has a 50-day simple moving average of $100.12 and a 200-day simple moving average of $79.92.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm's revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.03 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.